Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double …

FJ Neumann, A Kastrati, T Miethke, G Pogatsa-Murray… - The Lancet, 2001 - thelancet.com
Summary Background Vascular infection with Chlamydia pneumoniae might boost
inflammatory responses that play a pivotal part in neointima formation, which is the main …

The ACADEMIC study in perspective (Azithromycin in coronary artery disease: elimination of myocardial infection with Chlamydia)

JL Anderson, JB Muhlestein - The Journal of infectious diseases, 2000 - academic.oup.com
Chlamydia pneumoniae, a common cause of respiratory infection, is vasotropic and
frequently found in human atheromas. Whether it plays a causal role in coronary artery …

Randomized Secondary Prevention Trial of Azithromycin in Patients With Coronary Artery Disease and Serological Evidence for Chlamydia pneumoniae Infection …

JL Anderson, JB Muhlestein, J Carlquist, A Allen… - Circulation, 1999 - Am Heart Assoc
Background—Chlamydia pneumoniae commonly causes respiratory infection, is vasotropic,
causes atherosclerosis in animal models, and has been found in human atheromas …

[PDF][PDF] Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: a randomized placebo controlled trial

W Leowattana, N Mahanonda… - JOURNAL-MEDICAL …, 2001 - researchgate.net
The role of Chlamydia pneumoniae infection in precipitating acute coronary syndrome
(ACS) is unclear. Some studies have indicated that intervention with macrolide antibiotics …

Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study

JB Muhlestein, JL Anderson, JF Carlquist, K Salunkhe… - Circulation, 2000 - Am Heart Assoc
Background—Chlamydia pneumoniae is associated with coronary artery disease (CAD),
although its causal role is uncertain. A small preliminary study reported a> 50% reduction in …

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial

CM O'Connor, MW Dunne, MA Pfeffer, JB Muhlestein… - Jama, 2003 - jamanetwork.com
ContextSeveral lines of evidence have implied an association between Chlamydia
pneumoniae infection and atherogenesis. ObjectiveTo determine the effect of 12 weeks of …

[HTML][HTML] Antibiotic Treatment of Chlamydia pneumoniae after Acute Coronary Syndrome

CP Cannon, E Braunwald, CH McCabe… - New England journal …, 2005 - Mass Medical Soc
Background Chlamydia pneumoniae has been found within atherosclerotic plaques, and
elevated titers of antibody to this organism have been linked to a higher risk of coronary …

Endovascular Presence of Viable Chlamydia pneumoniaeIs a Common Phenomenon in Coronary Artery Disease

M Maass, C Bartels, PM Engel, U Mamat… - Journal of the American …, 1998 - jacc.org
Objectives. We sought to examine coronary arteries for the presence of viable bacteria of the
fastidious species Chlamydia pneumoniae. Background. The respiratory pathogen C …

Effect of Azithromycin Treatment on Endothelial Function in Patients With Coronary Artery Disease and Evidence of Chlamydia pneumoniae Infection

N Parchure, EG Zouridakis, JC Kaski - Circulation, 2002 - Am Heart Assoc
Background—It has been suggested that infection with Chlamydia pneumoniae (CPn) can
trigger inflammatory mechanisms that may in turn impair vascular endothelial function. The …

[HTML][HTML] Secondary prevention of atherosclerosis through Chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral …

T Vainas, FRM Stassen, GWH Schurink… - European journal of …, 2005 - Elsevier
BACKGROUND: Sero-epidemiological and experimental studies suggest that Chlamydia
pneumoniae infections play an important role in the development of atherosclerosis. Clinical …